drugset
Drugs / HGT-1110
last change May 2026 re-read 3 minutes ago

HGT-1110

also known as SHP611 · Recombinant human arylsulfatase A · TAK-611

Protein / enzyme biologic

Developed for
metachromatic leukodystrophy · metachromatic leukodystrophy, late infantile form
Investigated by
Shire · Takeda Development Center Americas, Inc.

Trials 3

today NCT03771898 · Ph 2 NCT01887938 · Ph 1/2 NCT01510028 · Ph 1/2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT01887938 May 2013 → Feb 2026 metachromatic leukodystrophy Shire Completed No outcome recorded
Phase 1/2 NCT01510028 Feb 2012 → Jan 2017 metachromatic leukodystrophy Shire Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT03771898 May 2019 → Mar 2023 metachromatic leukodystrophy, late infantile form Shire Completed Missed primary

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as HGT-1110 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01887938 ↗
Known as Recombinant human arylsulfatase A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510028 ↗
Known as SHP611 “We examined the safety and tolerability of intrathecally delivered recombinant human ASA (rhASA; SHP611, now TAK-611) in children with MLD (NCT01510028).” PMID 32792226 ↗ Jul 2020
1

NCT03771898 ↗
Known as TAK-611 “We examined the safety and tolerability of intrathecally delivered recombinant human ASA (rhASA; SHP611, now TAK-611) in children with MLD (NCT01510028).” PMID 32792226 ↗ Jul 2020
Modality Protein / enzyme biologic “recombinant human ASA (rhASA; SHP611, now TAK-611)” PMID 32792226 ↗ Jul 2020
Route Intrathecal “administered by intrathecal (IT) injection” NCT01510028 ↗